Actas dermo-sifiliograficas最新文献

英文中文

Treatment of Basosquamous Carcinoma With Sonidegib in a Patient with HIV 索地吉治疗HIV患者基底鳞状癌。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-04 DOI: 10.1016/j.ad.2025.104508

C. Fernández Romero , L. Vila Cobreros , P. Navarro Conde , E. Gimeno Carpio

引用次数: 0

Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification 根据太阳弹性分级的非足部皮肤色素性黑色素瘤的比较：支持新的世界卫生组织分类。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-04 DOI: 10.1016/j.ad.2025.104519

R. Moro , F. Mayo-Martínez , Z. García-Casado , M. Aguerralde-Martin , Victor Traves , E. Manrique-Silva , C. Requena , D.E. Elder , E. Nagore

Background and aims

The new WHO classification distinguishes two main pathogenic pathways for cutaneous melanoma, low and high-chronic sun damage (CSD). However, there are no studies to support its validity in the category of non-acral cutaneous lentiginous melanoma (NACLM). Thus, the aim of this study was to correlate the degree of solar elastosis (SE) with a range of clinicopathologic and genomic parameters in a cohort of NACLMs.

Material and methods

We conducted a retrospective cohort study of patients affected by an in situ or invasive NACLM distributed across three groups depending on the grade of SE. NACLM includes lentigo maligna melanoma and lentigo maligna, and other non-acral cutaneous lesions with a lentiginous growth pattern.

Results

The study included a total of 257 patients, 132 men (51.4%) and 125 women (48.6%) with a median age of 71 years. SE grade I was reported in 38 cases (14.8%), grade II in 61 cases (23.7%), and grade III in 158 cases (61.5%). Higher SE grade was related to head/neck location, older age at diagnosis and presence of lentigines in melanoma area. Lower SE grade was related to other locations, higher nevi count, presence of regression and BRAF V600E mutation (univariate logistic regression quantification: V600E vs WT; OR, 0.23; 95%CI, 0.05–1.06; p = 0.059).

Conclusion

SE grade is useful to classify NACLMs in different groups distinguished by their clinical, pathological, and molecular features. These results endorse the new WHO classification of low- and high-CSD melanomas. Moreover, they highlight the importance of reporting the grade of SE in the pathological report.

背景和目的：世卫组织的新分类区分了皮肤黑色素瘤的两种主要致病途径：低慢性和高慢性太阳损伤（CSD）。然而，尚无研究支持其在非肢端皮肤黄斑性黑色素瘤（NACLM）类别中的有效性。因此，本研究的目的是在NACLMs队列中将太阳弹性弹性（SE）的程度与一系列临床病理和基因组参数相关联。材料和方法：我们对原位或侵袭性NACLM患者进行了回顾性队列研究，根据SE的等级分为3组。NACLM包括恶性小晶状体黑色素瘤和恶性小晶状体，以及其他具有小晶状体生长模式的非肢端皮肤病变。结果：共纳入257例患者，其中男性132例（51.4%），女性125例（48.6%），中位年龄71岁。SE I级38例（14.8%），SE II级61例（23.7%），SE III级158例（61.5%）。SE等级越高，与头颈部位置、诊断时年龄越大以及黑素瘤区域存在小体有关。低SE等级与其他部位、高nevi计数、存在回归和BRAF V600E突变相关（单变量logistic回归量化：V600E vs WT； OR, 0.23; 95%CI, 0.05-1.06; p = 0.059）。结论：SE分级可以根据不同的临床、病理和分子特征对不同的NACLMs进行分类。这些结果支持世界卫生组织对低csd和高csd黑色素瘤的新分类。此外，他们还强调了在病理报告中报告SE分级的重要性。

{"title":"Comparison of Nonacral Cutaneous Lentiginous Melanomas According to the Degree of Solar Elastosis: Support for the New World Health Organization Classification","authors":"R. Moro , F. Mayo-Martínez , Z. García-Casado , M. Aguerralde-Martin , Victor Traves , E. Manrique-Silva , C. Requena , D.E. Elder , E. Nagore","doi":"10.1016/j.ad.2025.104519","DOIUrl":"10.1016/j.ad.2025.104519","url":null,"abstract":"<div><h3>Background and aims</h3><div>The new WHO classification distinguishes two main pathogenic pathways for cutaneous melanoma, low and high-chronic sun damage (CSD). However, there are no studies to support its validity in the category of non-acral cutaneous lentiginous melanoma (NACLM). Thus, the aim of this study was to correlate the degree of solar elastosis (SE) with a range of clinicopathologic and genomic parameters in a cohort of NACLMs.</div></div><div><h3>Material and methods</h3><div>We conducted a retrospective cohort study of patients affected by an in situ or invasive NACLM distributed across three groups depending on the grade of SE. NACLM includes lentigo maligna melanoma and lentigo maligna, and other non-acral cutaneous lesions with a lentiginous growth pattern.</div></div><div><h3>Results</h3><div>The study included a total of 257 patients, 132 men (51.4%) and 125 women (48.6%) with a median age of 71 years. SE grade I was reported in 38 cases (14.8%), grade II in 61 cases (23.7%), and grade III in 158 cases (61.5%). Higher SE grade was related to head/neck location, older age at diagnosis and presence of lentigines in melanoma area. Lower SE grade was related to other locations, higher nevi count, presence of regression and BRAF V600E mutation (univariate logistic regression quantification: V600E vs WT; OR, 0.23; 95%CI, 0.05–1.06; <em>p</em>  <!-->0.059).</div></div><div><h3>Conclusion</h3><div>SE grade is useful to classify NACLMs in different groups distinguished by their clinical, pathological, and molecular features. These results endorse the new WHO classification of low- and high-CSD melanomas. Moreover, they highlight the importance of reporting the grade of SE in the pathological report.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104519"},"PeriodicalIF":2.8,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Systematic Review of Treatments for Cutaneous Chronic Graft-versus-Host Disease 皮肤慢性移植物抗宿主病治疗的系统综述。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-04 DOI: 10.1016/j.ad.2025.104522

M. Zhou , M. Mansilla-Polo , P. Fernandez-Peñas

Chronic graft-versus-host disease (cGVHD) is a major multiple organ complication of allogeneic hematopoietic stem cell transplantation, and skin involvement is associated with substantial mortality, morbidity and reduction in quality of life. However, more than half of patients are refractory to current first-line therapy and there is still a lack of high-level evidence regarding alternative therapeutic agents. This systematic review was conducted by two independent reviewers who searched and screened records published from database inception to May 2024 in PubMed, Embase, and the Cochrane Central Register of Controlled Trials, using prespecified inclusion and exclusion criteria aligned with the study objective. Two reviewers assessed the risk of bias and quality of evidence of trials eligible for review. Seven randomized controlled trials of extracorporeal photopheresis (ECP) with standard therapy, imatinib, entospletinib with prednisone, ruxolitinib, and ibrutinib with prednisone were eligible for inclusion. Ruxolitinib demonstrated superiority versus standard therapy and placebo with an overall response rate of 41.5% and a reduction in body surface area affected from 14.5% down to 6.2%. No other treatments conferred a statistically significant benefit versus standard therapy or placebo. Entospletinib was markedly inferior to placebo. Although all 7 trials demonstrated some risk of bias, they were found to have a moderate-to-high quality of evidence. In conclusion, of all therapeutic agents reviewed, only ruxolitinib demonstrated high-level evidence of a modest efficacy in treating cutaneous cGVHD and should be considered as a line of therapy in addition to current first-line therapy. Further high-level studies are needed to identify alternative therapeutic agents and validate their efficacy profile.

慢性移植物抗宿主病（cGVHD）是异基因造血干细胞移植的主要多器官并发症，皮肤受累与大量死亡率、发病率和生活质量下降有关。然而，超过一半的患者对目前的一线治疗是难治的，并且仍然缺乏关于替代治疗药物的高水平证据。该系统评价由两名独立的审稿人进行，他们搜索并筛选了从数据库建立到2024年5月在PubMed、Embase和Cochrane中央对照试验登记册中发表的记录，使用与研究目标一致的预先指定的纳入和排除标准。两位审稿人评估了符合审评条件的试验的偏倚风险和证据质量。7项随机对照试验纳入了体外光化学（ECP）与标准治疗、伊马替尼、恩托替尼联合强尼松、鲁索利替尼和依鲁替尼联合强尼松的研究。Ruxolitinib显示出与标准疗法和安慰剂相比的优势，总缓解率为41.5%，受影响的体表面积从14.5%下降到6.2%。与标准治疗或安慰剂相比，没有其他治疗获得统计学上显著的益处。托普替尼的疗效明显低于安慰剂。虽然所有7项试验都显示出一定的偏倚风险，但发现它们具有中等到高质量的证据。综上所述，在所有的治疗药物中，只有ruxolitinib在治疗皮肤cGVHD方面表现出高水平的中等疗效，应该考虑作为目前一线治疗之外的一线治疗。需要进一步的高水平研究来确定替代治疗药物并验证其疗效。

{"title":"A Systematic Review of Treatments for Cutaneous Chronic Graft-versus-Host Disease","authors":"M. Zhou , M. Mansilla-Polo , P. Fernandez-Peñas","doi":"10.1016/j.ad.2025.104522","DOIUrl":"10.1016/j.ad.2025.104522","url":null,"abstract":"<div><div>Chronic graft-versus-host disease (cGVHD) is a major multiple organ complication of allogeneic hematopoietic stem cell transplantation, and skin involvement is associated with substantial mortality, morbidity and reduction in quality of life. However, more than half of patients are refractory to current first-line therapy and there is still a lack of high-level evidence regarding alternative therapeutic agents. This systematic review was conducted by two independent reviewers who searched and screened records published from database inception to May 2024 in PubMed, Embase, and the Cochrane Central Register of Controlled Trials, using prespecified inclusion and exclusion criteria aligned with the study objective. Two reviewers assessed the risk of bias and quality of evidence of trials eligible for review. Seven randomized controlled trials of extracorporeal photopheresis (ECP) with standard therapy, imatinib, entospletinib with prednisone, ruxolitinib, and ibrutinib with prednisone were eligible for inclusion. Ruxolitinib demonstrated superiority versus standard therapy and placebo with an overall response rate of 41.5% and a reduction in body surface area affected from 14.5% down to 6.2%. No other treatments conferred a statistically significant benefit versus standard therapy or placebo. Entospletinib was markedly inferior to placebo. Although all 7 trials demonstrated some risk of bias, they were found to have a moderate-to-high quality of evidence. In conclusion, of all therapeutic agents reviewed, only ruxolitinib demonstrated high-level evidence of a modest efficacy in treating cutaneous cGVHD and should be considered as a line of therapy in addition to current first-line therapy. Further high-level studies are needed to identify alternative therapeutic agents and validate their efficacy profile.</div></div>","PeriodicalId":7173,"journal":{"name":"Actas dermo-sifiliograficas","volume":"117 2","pages":"Article 104522"},"PeriodicalIF":2.8,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145695692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AEDV Sustainability Plan: A Commitment to Society AEDV可持续发展计划：对社会的承诺。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-04 DOI: 10.1016/j.ad.2025.104526

Y. Gilaberte

引用次数: 0

CO2 Laser Ablation for Multiple Miliary Osteoma Cutis: Diagnostic and Procedural Role of the “Spark Sign” Co₂激光消融治疗多发性军事性骨瘤：“火花征”的诊断和治疗作用。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-03 DOI: 10.1016/j.ad.2025.104502

P. López Sanz , D. Barco

引用次数: 0

Second-degree Burns: Contemporary Management, Evidence Gaps, and Practical Proposals 二度烧伤：当代管理，证据差距，和实际建议。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-03 DOI: 10.1016/j.ad.2025.104503

J. Ugedo Alzaga , E. Conde-Montero

引用次数: 0

Facial Lesions Transmission in the Context of Sexual Relations 性行为中面部损伤的传播。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-03 DOI: 10.1016/j.ad.2025.104501

M. Cotarelo Hernández , T. Puerta López , J.A. Pérez-García

引用次数: 0

Tralokinumab Effectiveness in Moderate-to-severe Atopic Dermatitis With Palmoplantar Eczema 曲洛单抗治疗中重度特应性皮炎伴掌跖湿疹的疗效。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-03 DOI: 10.1016/j.ad.2025.104494

J.J. Domínguez-Cruz , F.J. Navarro-Triviño , M. Galán-Gutiérrez , J.J. Pereyra-Rodríguez , J.C. Armario-Hita , R. Ruiz-Villaverde

引用次数: 0

Arborizing Vessels and Whitish Shiny Structures on a Salmon-colored Background: A Diagnostic Framework 在鲑鱼色的背景上，树突状的血管和白色闪亮的结构：一种诊断框架。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-03 DOI: 10.1016/j.ad.2025.104506

A. Barrutia-Etxebarria, R.M. Escribano De La Torre, J. Gimeno Castillo

引用次数: 0

Long-Term Real-World Persistence of Guselkumab in Patients With Moderate-to-Severe Psoriasis guelkumab在中重度牛皮癣患者中的长期实际持续治疗。

IF 2.8 Q1 DERMATOLOGY

Actas dermo-sifiliograficas

Pub Date : 2025-12-03 DOI: 10.1016/j.ad.2025.104493

J. Borrás-Blasco , R. Alcala , A. Valcuende-Rosique , S. Cornejo

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Actas dermo-sifiliograficas

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀